Advertisement

Inpharma Weekly

, Volume 1095, Issue 1, pp 13–14 | Cite as

Tazarotene: a new topical psoriasis therapy

  • Wayne Elwood
Newsletter Article
  • 4 Downloads

Abstract

Topical therapy is the mainstay of treatment for patients with mild-to-moderate psoriasis. Currently available topical agents generally only produce short-term relief and the condition recurs when treatment is stopped. Tazarotene is a new generation synthetic retinoid with specificity for retinoic acid receptors (RARs) that is available in Germany and has recently been approved in Canada and in the US as a once-daily treatment for patients with stable plaque psoriasis and facial acne vulgaris. Results from several Allergan-sponsored studies examining tazarotene’s pharmacology and clinical use in patients with stable plaque psoriasis were presented at the 19th World Congress of Dermatology [ Sydney, Australia; June 1997 ].

Keywords

Psoriasis Retinoic Acid Acne Retinoid Acid Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1997

Authors and Affiliations

  • Wayne Elwood

There are no affiliations available

Personalised recommendations